Diagnostic methods are evolving to measure the reaction
of the host to a specific disease challenge rather than
attempting to directly detect an antibody or pathogen.
CNAD’s technology platform delivers a repeatable and scalable process
for molecular diagnostic assay development.
Our bioinformatics platform and team of experts identify host biomarkers
in at very early stages of disease progress.
We develop diagnostic assays that can be run in a matter of hours on standard equipment.
CNAD has successfully demonstrated proof of concept with studies completed on radiation in rats, chronic wasting in elk, bovine spongiform encephalopathy (BSE) in cattle, and sepsis in humans.
CNAD's proprietary technology provides the possibility for accurate diagnostic tests to be used in the early stages of chronic diseases. CNAD's technology uses serum as the specimen, which is readily accessible and available already during routine testing procedures (non-invasive diagnostics). In the future, CNAD may be able to test for multiple conditions simultaneously, thus widening the range of chronic diseases, which can be determined at the earliest stages during routine testing procedures.